Related Experiment Video
Updated: Nov 20, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
Dat T Tran1,2, Dan Palfrey3, Robert Welsh4
1Institute of Health Economics, #1200-10405 Jasper Avenue, Edmonton, AB, T5J 3N4, Canada. dttran@ualberta.ca.
Insights
Healthcare costs for high-risk cardiovascular disease (HRCVD) patients were substantial, decreasing over time after the initial event. Secondary prevention patients incurred significantly higher costs than primary prevention patients.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Public Health
Background:
- Cardiovascular disease (CVD) poses a significant public health burden globally.
- Identifying and managing high-risk cardiovascular disease (HRCVD) patients is crucial for resource allocation and patient outcomes.
- Canadian Cardiovascular Society dyslipidemia guidelines define specific criteria for HRCVD.
Purpose of the Study:
- To calculate short- and long-term healthcare resource utilization and costs for adults with HRCVD.
- To compare costs between primary and secondary prevention patient groups.
- To analyze cost trends over time in HRCVD management.
Main Methods:
- Linked Alberta health databases for patients aged ≥18 years with HRCVD (FY2012-FY2016).
- Categorized patients into primary and secondary prevention groups based on the index event.
- Calculated resource use and costs for 5 years post-index event, with follow-up until March 2018.
Main Results:
- Included 459,739 HRCVD patients; 3% were secondary prevention.
- Secondary prevention patients were older, with fewer females, and incurred triple the first-year costs (CA$36,641 vs. CA$11,299) compared to primary prevention.
- Total first-year healthcare costs for HRCVD patients decreased from FY2012 (CA$1.16 billion) to FY2016 (CA$1.05 billion).
Conclusions:
- Healthcare costs for HRCVD patients are substantial but show a decreasing trend over time.
- Costs are highest in the year immediately following the index event and decline thereafter.
- Secondary prevention patients represent a higher-cost group compared to primary prevention patients.
Objective:
We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines.
Methods:
We linked Alberta health databases to identify patients aged ≥ 18 years with HRCVD between fiscal year (FY) 2012 and FY2016. The first HRCVD event was the index event. Patients were categorized into (1) primary prevention patients and (2) secondary prevention patients at the index event and were followed until death, they moved out of the province, or they were censored at March 2018. We calculated the resource use and costs for each of the 5 years after the index event.
Results:
The study included 459,739 HRCVD patients (13,947 [3%] were secondary prevention patients). The secondary prevention patients were older (median age 61 years vs. 55 years; p < 0.001), and there were fewer females in this group (30.4% vs. 51.3%; p < 0.001). The total healthcare costs in the first year decreased over time (FY2012: 1.16 billion Canadian dollars (CA$); FY2016: CA$1.05 billion; p < 0.001). An HRCVD patient incurred CA$12,068, CA$5626, and CA$4655 during the first, second, and fifth year, respectively (p for trend < 0.001). During the first year, healthcare costs per secondary prevention patient (CA$36,641) were triple that for a primary prevention patient (CA$11,299; p < 0.001), primarily due to higher hospitalization costs in secondary prevention patients (CA$26,896 vs. CA$6051; p < 0.001).
Conclusions:
The healthcare costs for HRCVD patients were substantial but decreased over time. The costs were highest in the year following the index event and decreased thereafter. Secondary prevention patients incurred higher costs than the primary prevention patients.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Atherosclerosis III: Management
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Hypertension and Regulation of Blood Pressure